Savings from sub-groups?: Policy guidance and Alzheimer's disease treatments
- 99 Downloads
A range of new therapeutic agents are now available for the management of Alzheimer's disease. With limited resources available however, policy-makers and other health care professionals have to prioritise and judge competing treatments on criteria such as the magnitude of clinical effectiveness and cost-effectiveness. Policy guidance that restricts treatments to defined patient sub-groups can improve the cost-effectiveness of treatments, and can help limit rises in health care expenditures. Budget impact models that estimate the amount of additional costs and potential savings are being increasingly used by policy-makers. However, the amount of savings estimated in such models depends on the effectiveness of treatment in changing morbidity, and the association between morbidity and costs.
To examine the magnitude of cost savings arising from provision of treatment to different patient sub-groups, using policy guidance decisions made by the National Institute for Health and Clinical Excellence (NICE) for cholinesterase inhibitor therapies in Alzheimer's Disease (AD) in the United Kingdom National Health Service (NHS).
Cohort simulation modelling.
Policy guidance decisions that restricted treatment to smaller patient sub-groups were associated with lower overall care costs, but did not reduce drug costs.
Given increasing recognition by health policy-makers of the importance of affordability of new treatments, greater attention should be paid to measurement of cost impacts by sub-groups within health economic modelling.
Key wordsAlzheimer's disease costs cost analysis dementia economics sub-groups budget impact donepezil cholinesterase inhibitor therapies
Unable to display preview. Download preview PDF.
- 2.Birks JS, Grimley Evans J, Iakovidou V, Tsolaki M. Rivastigmine for Alzheimer's disease. The Cochrane Library, Chichester, UK: John Wiley & Sons Ltd, Issue 2, 2004.Google Scholar
- 3.Birks JS, Harvey R. Donepezil for dementia due to Alzheimer's disease (Cochrane Review). Cochrane Database of Systematic Reviews. Cochrane Library, Chichester, UK: John Wiley & Sons Ltd, Issue 1, 2006.Google Scholar
- 4.Olin J, Schneider L. Galantamine for dementia due to Alzheimer's disease (Cochrane Review). The Cochrane Library, Chichester, UK: John Wiley & Sons Ltd, Issue 2, 2004.Google Scholar
- 21.National Institute for Health and Clinical Excellence. Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer's disease. Appraisal Consultation Document. London: National Institute for Health and Clinical Excellence, 2006.Google Scholar
- 22.National Institute for Health and Clinical Excellence. Donepezil, rivastigmine, galantamine, and memantine for the treatment of Alzheimer's disease. Appraisal Consultation Document. London: National Institute for Health and Clinical Excellence, 2005.Google Scholar
- 23.National Institute for Clinical Excellence. Guidance on the use of donepezil, rivastigmine and galantamine for the treatment of Alzheimer's disease. Technology Appraisal Guidance No.19. London: National Institute for Clinical Excellence, 2001.Google Scholar
- 24.National Institute for Clinical Excellence. Guide to the methods of technical appraisal. London: National Institute for Clinical Excellence, 2004.Google Scholar
- 25.Canadian Agency for Drugs and Technologies in Health. Guidelines for the economic evaluation of health technologies. Ottawa: Canadian Agency for Drugs and Technologies in Health, 2006.Google Scholar
- 26.Commonwealth Department of Health and Ageing. Guidelines for the Pharmaceutical Industry on Preparation of Submissions to the Pharmaceutical Benefits Advisory Committee. Canberra: Commonwealth of Australia, 2002.Google Scholar
- 27.National Statistics. T 03: England and Wales; estimated resident population by single year of age and sex; Mid-2002 Population Estimates 2004. (http://www.statistics.gov.uk/statbase/Expodata/Spreadsheets/D7024.xls).
- 35.Knapp M, Prince M. Dementia UK. London: Alzheimer's Society, 2007.Google Scholar
- 37.British Medical Association, Royal Pharmaceutical Society of Great Britain. British National Formulary. London: BMA, RPS, 2003.Google Scholar
- 38.HM Treasury. The Green Book: Appraisal and Evaluation in Central Government. London: TSO, 2003.Google Scholar